Evidence map›Paper›PMID 24593728›Full record

ArticleMedical physics2014

Human radiation dosimetry of 6-[18F]FDG predicted from preclinical studies.

Raymond F Muzic, Visvanathan Chandramouli, Hsuan-Ming Huang, Chunying Wu, Ahmad Hatami, Faramarz Ismail-Beigi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical physics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Exploring extended [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Raymond F MuzicDepartment of Radiology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106; and Case Center for Imaging Research, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106.
Visvanathan ChandramouliDepartment of Radiology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106.
Hsuan-Ming HuangDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106 and Case Center for Imaging Research, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106.
Chunying WuDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106 and Case Center for Imaging Research, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106.
Ahmad HatamiDepartment of Radiology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106.
Faramarz Ismail-BeigiDepartment of Medicine, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106.
Case Western Reserve University · USUniversity Hospitals Case Medical Center · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Novel PET Imaging of Glucose TransportR01DK082423 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI ISMAIL-BEIGI, FARAMARZ, MUZIC, RAYMOND F · 2009 to 2012
$1.4M
NCATS NIH HHS UL1 TR000439NIDDK NIH HHS R01 DK082423
6 · The paper itself

Abstract

purposeThe authors are developing 6-[(18)F]fluoro-6-deoxy-D-glucose (6-[(18)F]FDG) as an in vivo tracer of glucose transport. While 6-[(18)F]FDG has the same radionuclide half-life as 2-[(18)F]fluoro-2-deoxy-D-glucose (2-[(18)F]FDG) which is ubiquitously used for PET imaging, 6-[(18)F]FDG has special biologic properties and different biodistributions that make it preferable to 2-[(18)F]FDG for assessing glucose transport. In preparation for 6-[(18)F]FDG use in human PET scanning, the authors would like to determine the amount of 6-[(18)F]FDG to inject while maintaining radiation doses in a safe range.

methodsRats were injected with 6-[(18)F]FDG, euthanized at specified times, and tissues were collected and assayed for activity content. For each tissue sample, the percent of injected dose per gram was calculated and extrapolated to that for humans in order to construct predicted time-courses. Residence times were calculated as areas under the curves and were used as inputs to OLINDA/EXM in order to calculate the radiation doses.

resultsUnlike with 2-[(18)F]FDG for which the urinary bladder wall receives the highest absorbed dose due to urinary excretion, with 6-[(18)F]FDG there is little urinary excretion and osteogenic cells and the liver are predicted to receive the highest absorbed doses: 0.027 mGy/MBq (0.100 rad/mCi) and 0.018 mGy/MBq (0.066 rad/mCi), respectively. Also, the effective dose from 6-[(18)F]FDG, i.e., 0.013 mSv/MBq (0.046 rem/mCi), is predicted to be approximately 30% lower than that from 2-[(18)F]FDG.

conclusions6-[(18)F]FDG will be safe for use in the PET scanning of humans.

Indexed as

Fluorodeoxyglucose F18AnimalsBiological TransportFluorine RadioisotopesGlucoseHumansLiverMaleMultimodal ImagingPositron-Emission TomographyRadiation DosageRadiometryRadiopharmaceuticalsRatsRats, Sprague-DawleyReproducibility of ResultsFluorine RadioisotopesFluorodeoxyglucose F18GlucoseRadiopharmaceuticals

Identifiers

PMID24593728
PMCPMC3978342
OpenAlexW2035446252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.